Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.04% | 79.98 | 0.9% | $596.63m | |
| CELG | Celgene Corporation | 1.72% | 139.06 | 1.1% | $557.44m | |
| AMGN | Amgen Inc. | 1.00% | 183.71 | 1.1% | $431.76m | |
| BIIB | Biogen Inc. | 3.45% | 347.25 | 1.2% | $381.15m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.02% | 445.61 | 2.7% | $321.83m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -1.48% | 120.08 | 10.7% | $266.06m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.15% | 154.93 | 1.9% | $226.20m | |
| INCY | Incyte Corporation | -0.57% | 115.94 | 2.5% | $208.52m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 2.63% | 144.54 | 1.9% | $182.97m | |
| ILMN | Illumina, Inc. | -0.46% | 205.28 | 3.5% | $140.43m | |
| EXEL | Exelixis, Inc. | 0.38% | 29.13 | 6.5% | $134.73m | |
| CLVS | Clovis Oncology, Inc. | -3.59% | 81.54 | 16.5% | $126.62m | |
| BLUE | Bluebird Bio, Inc. | -2.86% | 139.20 | 17.3% | $118.51m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.05% | 51.26 | 16.9% | $111.85m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.24% | 94.89 | 4.4% | $105.02m |
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.